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therapy, survival is dismal and rarely exceeds 12
months. Recently, however, several reports suggest that
aggressive combined modality therapy, including
either radical pleurectomy or extrapleural pneumonec-
tomy, followed by chemotherapy and radiation, may
significantly prolong survival.3,5
Improvements in the detection of regional and distant
metastases are needed to identify patients most likely to
benefit from aggressive combined-modality treatment
regimens. Notably, most long-term survivors after com-
bined modality treatment have disease limited to the
pleural space without mediastinal lymph node or distant
metastases.4,5 Although computed tomography (CT)
and magnetic resonance imaging (MRI) are routinely
used to predict resectability,6 these imaging modalities
fail to accurately demonstrate chest wall or transdi-
aphragmatic invasion and have a poor sensitivity for
detecting mediastinal lymph node involvement.7,8
Morphometric analysis of primary tumor volume may
Malignant pleural mesothelioma is uncommon in theUnited States, but its incidence is rising. Because
of patterns of occupational asbestos exposure, the
annual incidence of 3000 new cases is expected to
increase by over 50% in the coming decade.1,2 Without
Objectives: The purpose of this study was to evaluate the utility of positron
emission tomography with F18-fluorodeoxyglucose in the preoperative eval-
uation and staging of malignant mesothelioma in patients who were candi-
dates for aggressive combined modality therapy.
Methods: Eighteen consecutive patients with biopsy-proven malignant
mesothelioma underwent positron emission tomographic scanning. The
results of positron emission tomographic imaging were compared with
results obtained by computed tomography, mediastinoscopy, thoracoscopy,
and pathologic examination of surgical specimens. All patients fasted and
received an average of 14.5 ± 2.7 mCi of F18-fluorodeoxyglucose for
positron emission tomographic scanning. Attenuation-corrected whole-body
and regional emission images of the chest and upper abdomen were acquired
and formatted into transaxial, coronal, and sagittal images.
Results: All primary malignant mesotheliomas accumulated F18-fluo-
rodeoxyglucose, and the mean standardized uptake value was 7.6 (range, 3.33-
14.85; n = 9). There were no false-negative results of positron emission tomog-
raphy. Identification of occult extrathoracic metastases by positron emission
tomography was the basis for excluding two patients from surgical therapy.
There were two false-positive results of positron emission tomography:
increased F18-fluorodeoxyglucose uptake in the contralateral chest that was
negative by thoracoscopic biopsy (n = 1) and increased abdominal F18-fluo-
rodeoxyglucose uptake after partial colectomy for diverticular disease (n = 1).
Conclusions: Positron emission tomography can identify malignant pleural
mesothelioma and appears to be a useful noninvasive staging modality for
patients being considered for aggressive combined modality therapy. (J
Thorac Cardiovasc Surg 2000;120:128-33)
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predict survival on the basis of T status, but it is a dif-
ficult and time-consuming technique that analyzes only
the local extent of disease.9
Uptake of the positron-emitting glucose analog F18-
fluorodeoxyglucose (FDG) is increased in metabolically
active malignant cells and is the basis for its widespread
use in positron emission tomography (PET) imaging.
FDG-PET is proving increasingly valuable in the preop-
erative staging of lung and other cancers.10-13 Because
PET reflects the metabolic activity of tissues, PET is
complementary to anatomic imaging studies, such as CT
or MRI. Although the precise role of PET in cancer treat-
ment algorithms is yet to be determined, multiple stud-
ies support the use of PET in the workup of patients with
lung, breast, colorectal, and head and neck cancers.14
Recently, Bénard and colleagues7 reported the ability of
PET to differentiate malignant mesothelioma from
benign pleura-based disease and suggested that it may
also be useful in preoperative staging. To evaluate the
utility of PET in the preoperative evaluation and staging
of malignant mesothelioma, we reviewed data collected
from a consecutive series of patients referred for treat-
ment of malignant mesothelioma. We hypothesized that
PET could improve detection of mediastinal lymph
nodes and distant metastatic disease, thereby facilitating
the selection of patients who would benefit from aggres-
sive combined modality treatment.
Methods
The records from 18 consecutive patients referred for treat-
ment of malignant pleural mesothelioma who underwent
FDG-PET studies between 1997 and 1999 were reviewed. All
patients had a diagnosis of mesothelioma established by
means of open or thoracoscopic pleural biopsy or by cyto-
logic examination of pleural fluid. Pathologic slides from
other hospitals were reviewed by our pathology department
to confirm the diagnosis. All patients underwent a compre-
hensive evaluation, which included history and physical
examination, chest radiography, pulmonary function testing,
CT of the chest and upper abdomen, and PET scans.
Additional diagnostic procedures, such as thoracoscopy,
laparoscopy, and mediastinoscopy, were obtained when clin-
ically indicated.
Eight of the PET scans were obtained at the University of
California San Francisco PET imaging center, and the other
10 scans were conducted at a total of 4 other centers. Similar
imaging protocols were used at each center. All patients were
asked to fast for at least 4 hours before PET scanning.
Normoglycemia was confirmed by measurement of capillary
blood glucose levels. Approximately 40 minutes after the
intravenous administration of 14.5 ± 2.7 mCi of FDG,
patients were placed in the supine position in the PET scan-
ner (Siemens ECAT; Siemens-Elema, Division of Elema-
Schönander, Inc, Solna, Sweden). Separate attenuation-cor-
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rected transmission and emission scans of the thorax and
upper abdomen were acquired in two bed positions. Whole
body emission scans from the base of the skull to the thighs
were acquired in 6 bed positions. Images were reconstructed
in the transaxial, coronal, and sagittal planes.
PET scans were interpreted independently by an experi-
enced nuclear medicine physician. CT reports were available
for comparison. PET images were considered to be positive
for malignancy if there was focal hypermetabolic activity
with FDG uptake greater than background or mediastinal
activity. Standardized uptake value (SUV) was available for
the last 9 patients in the series and was calculated as
described.15 PET scan reports also included the likelihood of
malignancy in the contralateral chest, mediastinal lymph
nodes, or extrathoracic sites. Mediastinal lymph nodes were
defined as positive if discrete mediastinal foci of FDG uptake
not located within the pleural reflection could be identified.
Patient management decisions were based on the combined
interpretation of CT and PET images. Patients with suspect-
ed metastatic disease involving the contralateral chest, medi-
astinal lymph nodes, or extrathoracic sites underwent confir-
matory diagnostic procedures (including thoracoscopy of the
contralateral chest, mediastinoscopy, laparoscopy, or open
incisional biopsy). Patients found to have disease limited to
the pleural space without metastases underwent aggressive
combined modality therapy consisting of radical pleurectomy
and decortication, mediastinal lymph node sampling, and
intraoperative radiotherapy followed by postoperative
chemotherapy and radiation. Complete mediastinal lymph
node dissections were not routinely performed. All PET and
CT scans were reviewed in conjunction with pathology
reports from biopsy, surgical specimens, or autopsy reports.
Results
A total of 18 consecutive patients with pleural
mesothelioma were evaluated with PET scanning. The
median age was 68 years (range, 43-83 years), and the
male/female ratio was 14:4. A history of asbestos expo-
sure was documented in 13 (72%) patients, and 14
(78%) patients reported a history of tobacco use. The
mesothelioma cell type was epithelial or mixed in 17
(94%) patients and was sarcomatous in 1 (6%) patient.
Eleven (61%) patients had mesothelioma of the right
side of the chest, and 7 (39%) patients had tumors of
the left side of the chest. Ten (56%) patients had under-
gone talc pleurodesis for the treatment of effusions
associated with malignant mesothelioma (ranging from
1 to 24 months before PET scanning). Twelve (67%)
patients were treated with aggressive combined modal-
ity treatment consisting of radical pleurectomy and
decortication with intraoperative radiotherapy followed
by postoperative chemotherapy and radiation. In 2
(11%) patients radical pleurectomy was attempted but
was aborted because of extensive chest wall invasion.
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Four (22%) patients who were found to have metas-
tases to mediastinal lymph nodes or extrathoracic sites
did not undergo radical pleurectomy.
All 18 primary mesotheliomas accumulated signifi-
cant amounts of FDG, and the mean SUV of these
tumors was 7.5 ± 4.2. The pattern of FDG uptake typi-
cally matched the CT and intraoperative findings with
regard to the extent of pleural involvement and tumor
burden. Involvement of the interlobar fissures, as well
as the diaphragmatic surfaces, was also clearly demon-
strated by PET (Fig 1). The presence of pleural effusion
did not interfere with FDG uptake. However, PET
failed to predict transdiaphragmatic involvement or
chest wall invasion in 2 patients.
PET scanning identified increased FDG uptake in
mediastinal lymph nodes in 4 patients (Fig 2). In all 4
subjects lymph node metastases were confirmed by
pathologic examination of either biopsy or surgical
specimens. PET did not demonstrate lymph node
involvement in the remaining 14 (78%) patients, and
absence of lymph node involvement was confirmed by
pathologic examination in 12 of these 14 cases. In con-
trast, CT demonstrated lymph node enlargement in
only 2 of the 4 subjects with documented lymph node
metastases. In 2 patients CT gave false-positive results
by detecting enlarged lymph nodes, which were benign
by pathologic examination.
Overall, PET correctly identified the presence or
absence of metastatic disease in 16 (89%) of the 18
patients. Identification of occult extrathoracic metas-
tases, including axillary and cervical lymph node
metastases and bone metastases, by PET was the basis
for excluding 2 patients from surgical therapy. PET
also confirmed the CT finding of a contralateral lung
metastasis in 1 patient. In 2 patients negative PET scans
also confirmed that contralateral pleural abnormalities
identified by CT were benign. In 2 patients increased
FDG uptake by benign processes resulted in false-pos-
itive PET scans. In 1 case increased pleural uptake in
the contralateral chest was falsely interpreted as
metastatic disease. Notably, the intensity of FDG
uptake was less than the uptake by the patient’s prima-
ry tumor, and thoracoscopy with multiple biopsies was
consistent with a benign asbestos-related plaque.
Another patient who had undergone a partial colecto-
my for diverticulitis 2 months previously had an
abdominal focus of increased FDG uptake that repre-
sented residual hypermetabolic activity.
The accuracy of the PET scans in detecting metasta-
tic disease in mediastinal lymph nodes or distant sites
Fig 1.  Transverse (left) and coronal (right) PET images demonstrating extensive involvement of pleural surfaces,
including interlobar fissures and diaphragmatic surfaces, by mesothelioma.
Fig 2.  Left, Transverse PET image displaying increased focus of FDG uptake by mediastinal lymph nodes. Right,
Coronal section of a patient with extensive metastases to mediastinal, porta hepatis, and celiac lymph nodes.
intense glucose uptake by the primary tumor can
make it difficult to distinguish between involved N1
(intrapleural nodes) and the primary tumor. This def-
inition is supported by Sugarbaker’s staging system,5
wherein extrapleural, as opposed to intrapleural,
nodal involvement is specifically associated with an
adverse prognosis. Our data suggest that by detecting
extrapleural nodal disease, PET may improve patient
selection for combined modality treatment.
When compared with CT as a staging modality for
malignant mesothelioma, PET has both advantages and
disadvantages. In our experience, PET does not accu-
rately predict the presence or extent of local invasion
into the chest wall, pericardium, or diaphragm. The
greater anatomic detail afforded by CT and MRI is
more useful for imaging the local extent of disease and
predicting resectability. Indeed, the sensitivity of CT
and MRI for predicting resectability exceeds 90%.6
PET, however, provides complementary information by
distinguishing benign from malignant pleura-based
disease.7 Because PET identifies tissues with increased
glucose uptake, false-positive results may occur at sites
of inflammation.18 However, only 2 false-positive
results were identified by PET in our series compared
with the 4 false-positive results obtained with CT
(Table I). Importantly, PET identified undetected dis-
tant metastases in 2 patients, preventing aggressive
treatment that was unlikely to improve their survival.
Nonetheless, PET scan findings must still be correlated
with CT findings and the clinical picture. When dis-
crepancies occur and the PET scan does not fit the clin-
ical picture, surgical staging (eg, mediastinoscopy, tho-
racoscopy, and open biopsy) remains definitive and
necessary.
Although our data support the use of PET as a stag-
ing modality for malignant mesothelioma, the best
method to analyze the accuracy of PET would be a
comparison of PET, CT, and pathologic analysis in
prospective fashion. Our study is limited by its retro-
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is summarized in Table I. Two patients with extensive
chest wall involvement could not undergo radical
pleurectomy and did not have mediastinal lymph nodes
sampled. The remaining 16 patients had histologic
examination of mediastinal lymph nodes or distant
metastases confirmed. Of these 16 patients, PET cor-
rectly predicted the presence or absence of metastatic
disease in 14 patients. In contrast, CT correctly pre-
dicted the presence or absence of metastatic disease in
only 8 of 16 patients.
Discussion
Our findings suggest that PET is a useful imaging
modality for the preoperative staging of malignant
mesothelioma. These results are consistent with find-
ings recently reported by Bénard and colleagues,7 who
found that PET had a sensitivity and specificity of 91%
and 100%, respectively, for the identification of pri-
mary mesotheliomas. They found that PET results
were positive for lymph node metastases in 12 of 24
patients with mesothelioma, but only 10 of 24 patients
had confirmation by surgical staging. Nonetheless, in
the subjects with pathologic confirmation, they report-
ed a sensitivity and specificity of 83% and 75% of PET
for lymph node metastases. Our results also suggest
that PET may identify involvement of mediastinal
lymph nodes or extrathoracic sites that are underap-
preciated by CT.
It is a common but incorrect belief that mesothe-
lioma tends to progress locally, and lymph node or
distant metastases may rarely occur. Although
mesothelioma tends to progress locally rather than
systemically, lymph node metastases may be present
more often than was formerly believed. In addition,
several recently published trials of aggressive com-
bined modality treatment have emphasized the
adverse effect of nodal metastases on survival.4,5
Rusch and Venkatraman4 reported that among 89
patients who underwent lymph node dissections, 50%
had metastases to N2 mediastinal nodes. Sugarbaker
and colleagues5 found that positive extrapleural
lymph node status significantly shortened survival
after extrapleural pneumonectomy followed by
chemotherapy and radiation. Accordingly, staging
systems recently proposed by both the International
Mesothelioma Interest Group16 and Sugarbaker’s
group5 place greater importance on nodal status than
the system previously described by Butchart and col-
leagues.17 In this study we classified only discrete,
nonadjacent mediastinal foci of FDG uptake as a pos-
itive result indicating nodal disease. This is because
the poor spatial resolution of PET combined with the
Table I.  Efficacy of PET and CT scans in detecting
mediastinal lymph nodes or distant metastatic disease
CT PET
True positive 3 5
True negative 5 9
False positive 4 2
False negative 4 0
Analysis includes 16 patients who had pathologic examination of mediastinal
lymph nodes (n = 14) or distant metastases confirmed by other methods (biop-
sy or CT, n = 2). A patient was considered to have metastatic disease if involve-
ment of mediastinal lymph nodes, distant sites, or both was identified.
spective design, small sample size, and the absence of
mediastinal lymph node sampling in every patient.
Without complete mediastinal lymph node dissection,
including internal mammary and peridiaphragmatic
nodes, in each patient, it is impossible to determine the
exact sensitivity and specificity of PET for detecting
metastatic disease. Moreover, approximately one half
of our patients underwent talc pleurodesis before PET
scanning, which may have falsely elevated the amount
of FDG uptake. Further studies are warranted to assess
the utility of PET and other staging modalities, such as
mediastinoscopy, in the staging of mesothelioma.
In conclusion, PET appears to be a useful imaging
modality for the evaluation and staging of malignant
mesothelioma. Because PET images tumors on the
basis of their biologic behavior, it is particularly valu-
able for distinguishing between benign and malignant
pleural processes. Moreover, PET may also allow
noninvasive staging of mediastinal nodal status and
extrathoracic metastases. False-positive results may
occasionally be produced by nonmalignant process-
es; however, a negative PET scan result provides
strong evidence that the lesion is benign. On the basis
of our findings, we routinely obtain both CT and PET
scans on all patients referred for the evaluation of
mesothelioma. By identifying the metastatic spread
of disease preoperatively, we believe that PET may
improve the selection of patients who are most likely
to benefit from aggressive multimodality therapy for
mesothelioma.
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Discussion
Dr Eric Vallieres (Seattle, Wash). You and your colleagues
have shown us another potentially powerful use of PET in the
workup and staging of a thoracic malignancy. I am also for-
tunate to have on-site access to this technology, and I appre-
ciate almost on a daily basis the additional diagnostic staging
and prognostic information the test provides me and my can-
cer patients. PET scanning is now recognized as a staging
tool for lung cancer, lymphoma, and a growing number of
other malignant diseases. Universal access to PET scanning
remains an issue, however, but as its value becomes recog-
nized, this limitation should disappear. Reports like this one
are needed, and they will serve to establish the place of this
test in the evaluation of patients with mesothelioma. The
group at the University of Pennsylvania, as you have cited,
has already indicated how useful PET may possibly be in dif-
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ferentiating benign and malignant pleural changes, a some-
times very difficult differentiation to make in asbestos-
exposed patients who have pleural changes by conventional
imaging.
In this series of 18 patients with a proven diagnosis of
mesothelioma, PET scanning is shown to be a powerful
mediastinal staging noninvasive tool with a reported sensi-
tivity of 100% in the 16 patients in whom pathologic cor-
relation was available. This compares with a 43% sensitiv-
ity for CT scan. We know that the presence of N2 disease
in mesothelioma carries a bad prognosis that is probably
not altered by therapy. Hence, it is important to select out
these patients before submitting them to potentially very
morbid and costly multimodality therapy. The same argu-
ment applies to the identification of unsuspected systemic
metastasis in these patients, 2 (11%) of 18 in your series,
sparing a probably futile aggressive therapy in view of the
PET findings. The numbers are small but compare with the
range of 17% to 20% of patients with potentially resectable
lung cancer in whom unsuspected M1 disease is identified
by means of PET scanning. It is a great test, but one has to
be careful, and as shown in this report, a positive PET does
not always indicate cancer. False positivity is low but
exists, and we have to be careful not to write off patients
with a chance at cure without histologic confirmation of the
suspected findings.
Dr Schneider, I have 3 questions regarding your presenta-
tion. We know from the growing lung cancer PET literature
that emission scans may underestimate the activity in medi-
astinal lymph nodes, particularly when the tumor is central or
paramediastinal, such as that found with mesothelioma.
These nodes, however, can be seen and better evaluated by
attenuation-corrected transmission scans. Were attenuation-
corrected transmission scans of the mediastinal area obtained
in all patients? If so, why was an SUV available in only 6 of
your patients?
Dr Schneider. Thank you for your comments. With regard
to your first question, we did obtain attenuation-corrected
transmission images in all of our patients. However, a num-
ber of these PET scans were not performed at UCSF, and we
are actually in the process of gathering all those data and
reviewing the SUVs on the entirety of our series right now.
Dr Vallieres. More than half of your patients had received
a talc pleurodesis before the PET evaluation. It is known that
inflammatory changes are usually “hot” on PET, and the
patient with a healing colonic anastomosis proved that point
in your series. How early after this pleurodesis were the PET
scans obtained, and do you think that the inflammation of
pleurodesis may have somehow influenced the data present-
ed, particularly in regard to the mean SUV reported in your
document?
Dr Schneider. It is entirely possible that talc pleurodesis
did affect some of the SUVs that were obtained. Some of the
talc pleurodeses were as little as 3 or 4 weeks before the PET
scanning. Nonetheless, all the tumors did have increased
FDG uptake. We particularly wanted to evaluate areas outside
of the area where the talc was applied, such as the medi-
astinum and distant sites.
Dr Vallieres. Finally, your numbers remain small, but this
is the largest series on the topic to date, and a sensitivity of
100% is to be noted. In your opinion, what is the role of
mediastinoscopy in staging the mediastinum in a potential
candidate for multimodality therapy in this era of PET scan-
ning?
Dr Schneider. We have recently started doing medi-
astinoscopy in some of our patients with mesothelioma, in
particular those who have positive PET scan results, just to
confirm that those lymph nodes are indeed positive and not a
false-positive result. We have been routinely performing
mediastinoscopy in patients with positive PET scan results
for mediastinal nodes.
Dr Vallieres. If the PET is “cold,” you do not?
Dr Schneider. We have to combine the PET results with all
the different imaging modalities and the clinical picture as
well. Therefore, if the PET does not fit the picture, then we
use these other tests such as mediastinoscopy. We have not
come up with a formal protocol, but we are using medi-
astinoscopy more frequently.
